Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors?

References

• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60. (b) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759–72. (b) Del Prete S, Vullo D, De Luca V, et al. Biochemical characterization of the δ-carbonic anhydrase from the marine diatom Thalassiosira weissflogii, TweCA. J Enzyme Inhib Med Chem 2014;29:906–11. (c) Del Prete S, Vullo D, De Luca V, et al. Biochemical characterization of recombinant beta-carbonic anhydrase (PgiCAb) identified in the genome of the oral pathogenic bacterium Porphyromonas gingivalis. J Enzyme Inhib Med Chem 2015;30:366–70.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT, Capasso C. The eta-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin Ther Targets 2015;1:551–63. (b) Del Prete S, De Luca V, De Simone G, et al. Cloning, expression and purification of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum. J Enzyme Inhib Med Chem 2016;31(Suppl.4):54–9. (c) Vullo D, Del Prete S, Fisher GM, et al. Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum. Bioorg Med Chem 2015;23:526–31.
   Web of Science ®Google Scholar
• (a) Zimmerman S, Innocenti A, Casini A, et al. Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. Bioorg Med Chem Lett 2004;1:6001–6. (b) Supuran CT, Capasso C. An overview of the bacterial carbonic anhydrases. Metabolites 2017;7:E56. (c) Nocentini A, Vullo D, Del Prete S, et al. Inhibition of the β-carbonic anhydrase from the dandruff-producing fungus Malassezia globosa with monothiocarbamates. J Enzyme Inhib Med Chem 2017;32:1064–70.
   Web of Science ®Google Scholar
• (a) Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem 2015;3:325–32. (b) Supuran CT, Capasso C. Carbonic anhydrase from Porphyromonas gingivalis as a drug target. Pathogens 2017;6:E30. (c) Supuran CT, Capasso C. New light on bacterial carbonic anhydrases phylogeny based on the analysis of signal peptide sequences. J Enzyme Inhib Med Chem 2016;3:1254–60. (d) Ferraroni M, Del Prete S, Vullo D, et al. Crystal structure and kinetic studies of a tetrameric type II β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. Acta Crystallogr D Biol Crystallogr 2015;71:2449–56.
   Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467–74. (b) Ozensoy Guler O, Capasso C, Supuran CT. A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. J Enzyme Inhib Med Chem 2016;31:689–94.
   PubMed Web of Science ®Google Scholar
• (a) Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;1:199–229. (b) Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol 2016;12:423–31.
   Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnologic use for CO2 capture. J Enzyme Inhib Med Chem 2013;28:229–30. (b) Alterio V, Langella E, Viparelli F, et al. Structural and inhibition insights into carbonic anhydrase CDCA1 from the marine diatom Thalassiosira weissflogii. Biochimie 2012;94:1232–41. (c) Moya A, Tambutté S, Bertucci A, et al. Carbonic anhydrase in the scleractinian coral Stylophora pistillata: characterization, localization, and role in biomineralization. J Biol Chem 2008;283:25475–84. (d) Bertucci A, Moya A, Tambutté S, et al. Carbonic anhydrases in anthozoan corals—a review. Bioorg Med Chem 2013;21:1437–50. (e) Dathan NA, Alterio V, Troiano E, et al. Biochemical characterization of the chloroplastic β-carbonic anhydrase from Flaveria bidentis (L.) “Kuntze”. J Enzyme Inhib Med Chem 2014;29:500–4.
   PubMed Web of Science ®Google Scholar
• (a) Vullo D, De Luca V, Del Prete S, et al. Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune. Bioorg Med Chem 2015;23:1728–34. (b) Supuran CT. Bacterial carbonic anhydrases as drug targets: towards novel antibiotics? Front Pharmacol 2011;2:34. (c) Maresca A, Vullo D, Scozzafava A, et al. Inhibition of the beta-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids. J Enzyme Inhib Med Chem 2013;28:392–6.
   PubMed Web of Science ®Google Scholar
• (a) Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;1:4421–68. (b) De Simone G, Alterio V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. Expert Opin Drug Discov 2013;8:793–810. (c) De Simone G, Langella E, Esposito D, et al. Insights into the binding mode of sulphamates and sulphamides to hCA II: crystallographic studies and binding free energy calculations. J Enzyme Inhib Med Chem 2017;32:1002–11. (d) Di Fiore A, De Simone G, Alterio V, et al. The anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog strongly inhibit carbonic anhydrases: solution and X-ray crystallographic studies. Org Biomol Chem 2016;14:4853–8.
   Web of Science ®Google Scholar
• (a) Winum JY, Supuran CT. Recent advances in the discovery of zinc binding motifs for the development of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2015;30:321–4. (b) De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012;111:117–29.
   PubMed Web of Science ®Google Scholar
• (a) Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007–2011. Expert Opin Ther Pat 2012;22:79–88. (b) Masini E, Carta F, Scozzafava A, Supuran CT. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013;23:705–16. (c) Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 2012;27:138–47.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). Expert Opin Ther Pat 2013;23:681–91.
   PubMed Web of Science ®Google Scholar
• (a) Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;2:725–35. (b) Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2012;17:11–5.
   Web of Science ®Google Scholar
• (a) Bibi D, Mawasi H, Nocentini A, et al. Design and comparative evaluation of the anticonvulsant profile, carbonic-anhydrate inhibition and teratogenicity of novel carbamate derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide. Neurochem Res 2017;4:1972–82. (b) Carta F, Birkmann A, Pfaff T, et al. Lead development of thiazolylsulfonamides with carbonic anhydrase inhibitory action. J Med Chem 2017;6:3154–64. (c) Supuran CT, Kalinin S, Tanç M, et al. Isoform-selective inhibitory profile of 2-imidazoline-substituted benzene sulfonamides against a panel of human carbonic anhydrases. J Enzyme Inhib Med Chem 2016;31(Supp1.1):197–202. (d) Aggarwal M, Kondeti B, McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013;23:717–24.
   Web of Science ®Google Scholar
• (a) Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013). Expert Opin Ther Pat 2013;2:737–49. (b) Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;7:3364–76. (c) Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA Consortium. J Enzyme Inhib Med Chem 2015;30:689–721.
   Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:E48. (b) Federici C, Lugini L, Marino ML, et al. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J Enzyme Inhib Med Chem 2016;31(Suppl.1):119–25. (c) Kusuzaki K, Matsubara T, Murata H, et al. Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery? J Enzyme Inhib Med Chem 2017;3:908–16. (d) Bragagni M, Carta F, Osman SM, et al. Synthesis of an acridine orange sulfonamide derivative with potent carbonic anhydrase IX inhibitory action. J Enzyme Inhib Med Chem 2017;32:701–6.
   PubMed Web of Science ®Google Scholar
• Supuran CT. The safety and clinical efficacy of acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother 2015;15:851–6.
   PubMed Web of Science ®Google Scholar
• (a) Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem 2016;3:894–9. (b) Bejaoui M, Panatzi E, De Luca V, et al. Acetazolamide protects steatotic liver grafts against cold ischemia reperfusion injury. J Pharmacol Exp Ther 2015;355:191–8.
   Web of Science ®Google Scholar
• (a) Carta F, Di Cesare Mannelli L, Pinard M, et al. A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects. Bioorg Med Chem 2015;2:1828–40. (b) Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 2016;16:961–8. (c) Fragai M, Comito G, Di Cesare Mannelli L, et al. Lipoyl-homotaurine derivative (ADM_12) reverts oxaliplatin-induced neuropathy and reduces cancer cells malignancy by inhibiting carbonic anhydrase IX (CAIX). J Med Chem 2017;60:9003–11.
   Web of Science ®Google Scholar
• (a) Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31(Suppl.4):60–3. (b) Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;6:1159–70. (c) Angeli A, Tanini D, Capperucci A, Supuran CT. Synthesis of novel selenides bearing benzenesulfonamide moieties as carbonic anhydrase I, II, IV, VII, and IX inhibitors. ACS Med Chem Lett 2017;8:1213–7.
   Web of Science ®Google Scholar
• (a) Capasso C, Supuran CT. Anti-infective carbonic anhydrase inhibitors: a patent and literature review. Expert Opin Ther Pat 2013;2:693–704. (b) Capasso C, Supuran CT. Sulfa and trimethoprim-like drugs – antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors. J Enzyme Inhib Med Chem 2014;2:379–87. (c) Schlicker C, Hall RA, Vullo D, et al. Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. J Mol Biol 2009;3:1207–20. (d) Aspatwar A, Hammarén M, Koskinen S, et al. β-CA-specific inhibitor dithiocarbamate Fc14-584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis. J Enzyme Inhib Med Chem 2017;32:832–40.
   Web of Science ®Google Scholar
• (a) Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the beta-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2013;2:407–11. (b) Vermelho AB, da Silva Cardoso V, Ricci Junior E, et al. Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi. J Enzyme Inhib Med Chem 2018;33:139–46. (c) Nocentini A, Cadoni R, Del Prete S, et al. Benzoxaboroles as efficient inhibitors of the β-carbonic anhydrases from pathogenic fungi: activity and modeling study. ACS Med Chem Lett 2017;8:1194–8. (d) Vullo D, Kumar RSS, Scozzafava A, et al. Sulfonamide inhibition studies of the β-carbonic anhydrase from the bacterial pathogen Clostridium perfringens. J Enzyme Inhib Med Chem 2018;33:31–6. (e) De Vita D, Angeli A, Pandolfi F, et al. Inhibition of the α-carbonic anhydrase from Vibrio cholerae with amides and sulfonamides incorporating imidazole moieties. J Enzyme Inhib Med Chem 2017;32:798–804.
   Web of Science ®Google Scholar
• (a) Köhler K, Hillebrecht A, Schulze Wischeler J, et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl 2007;4:7697–9. (b) Scozzafava A, Menabuoni L, Mincione F, Supuran CT. Carbonic anhydrase inhibitors. A general approach for the preparation of water soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long lasting, topical intraocular pressure lowering properties. J Med Chem 2002;4:1466–76. (c) Carta F, Garaj V, Maresca A, et al. Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: solution and X-ray crystallographic studies. Bioorg Med Chem 2011;1:3105–19. (d) Vomasta D, Innocenti A, König B, Supuran CT. Carbonic anhydrase inhibitors: two-prong versus mono-prong inhibitors of isoforms I, II, IX, and XII exemplified by photochromic cis-1,2-α-dithienylethene derivatives. Bioorg Med Chem Lett 2009;19:1283–6.
   Web of Science ®Google Scholar
• (a) Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896–902. (b) Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun 2010;46:8371–3.
   PubMed Web of Science ®Google Scholar
• (a) Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg Med Chem Lett 2004;1:5427–33. (b) Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors. Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 2005;1:3102–8. (c) Carta F, Scozzafava A, Supuran CT. Sulfonamides (RSO2NH2): a patent review 2008–2012. Expert Opin Ther Pat 2012;22:747–58. (d) Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. Part 74. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem 1999;4:2641–50. (e) Borras J, Scozzafava A, Menabuoni L, et al. Carbonic anhydrase inhibitors. Part 73. Synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring? Bioorg Med Chem 1999;7:2397–406. (f) Abbate F, Winum JY, Potter BV, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg Med Chem Lett 2004;14:231–4.
   Web of Science ®Google Scholar
• (a) Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. J Med Chem 2012;55:1721–30. (b) Monti SM, Maresca A, Viparelli F, et al. Dithiocarbamates strongly inhibit the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata. Bioorg Med Chem Lett 2012;22:859–62. (c) Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. Chem Commun 2012;4:1868–70. (d) Bozdag M, Carta F, Vullo D, et al. Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action. Bioorg Med Chem 2015;23:2368–76.
   PubMed Web of Science ®Google Scholar
• Carta F, Akdemir A, Scozzafava A, et al. Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo. J Med Chem 2013;56:4691–700.
   PubMed Web of Science ®Google Scholar
• (a) Vullo D, Durante M, Di Leva FS, et al. Monothiocarbamates strongly inhibit carbonic anhydrases in vitro and possess intraocular pressure lowering activity in an animal model of glaucoma. J Med Chem 2016;5:5857–67. (b) Nocentini A, Vullo D, Del Prete S, et al. Inhibition of the β-carbonic anhydrase from the dandruff-producing fungus Malassezia globosa with monothiocarbamates. J Enzyme Inhib Med Chem 2017;32:1064–70.
   Web of Science ®Google Scholar
• (a) Carta F, Innocenti A, Hall RA, et al. Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic-/aromatic carboxylates and their derivatives. Bioorg Med Chem Lett 2011;21:2521–6. (b) Innocenti A, Vullo D, Scozzafava A, et al. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2005;15:573–8. Interaction of isozymes I, II, IV, V and IX with carboxylates. (c) Maresca A, Vullo D, Scozzafava A, et al. Inhibition of the beta-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids. J Enzyme Inhib Med Chem 2013;28:392–6. (d) Mori M, Cau Y, Vignaroli G, et al. Hit recycling: discovery of a potent carbonic anhydrase inhibitor by in silico target fishing. ACS Chem Biol 2015;10:1964–9. (e) Langella E, D’Ambrosio K, D’Ascenzio M, et al. A combined crystallographic and theoretical study explains the capability of carboxylic acids to adopt multiple binding modes within carbonic anhydrase active site. Chemistry 2016;22:97–100. (f) D’Ambrosio K, Carradori S, Monti SM, et al. Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem Commun 2015;51:302–5. (g) Cau Y, Vullo D, Mori M, et al. Potent and selective carboxylic acid inhibitors of tumor-associated carbonic anhydrases IX and XII. Molecules 2018;23:E17. (h) Cadoni R, Pala N, Lomelino C, et al. Exploring heteroaryl-pyrazole carboxylic acids as human carbonic anhydrase XII inhibitors. ACS Med Chem Lett 2017;8:941–6.
   PubMed Web of Science ®Google Scholar
• (a) Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors. Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of carbonic anhydrase isozymes I, II and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000;43:3677–87. (b) de Menezes Dda R, Calvet CM, Rodrigues GC, et al. Hydroxamic acid derivatives: a promising scaffold for rational compound optimization in Chagas disease. J Enzyme Inhib Med Chem 2016;31:964–73. (c) Scozzafava A, Supuran CT. Hydroxyurea is a carbonic anhydrase inhibitor. Bioorg Med Chem 2003;11:2241–6. (d) Nuti E, Orlandini E, Nencetti S, et al. Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylatedhydroxamates. Bioorg Med Chem 2007;15:2298–311. (e) Santos MA, Marques S, Vullo D, et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated isoforms I, II and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties. Bioorg Med Chem Lett 2007;17:1538–43. (f) Supuran CT. Hydroxamates as carbonic anhydrase inhibitors. In: Gupta SP, ed. Hydroxamic acids: a unique family of chemicals with multiple biological activities. Heidelberg: Springer Verlag; 2013:55–69.
   Google Scholar
• (a) Reich R, Hoffman A, Veerendhar A, et al. Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment. J Med Chem 2012;55:7875–82. (b) Tauro M, Loiodice F, Ceruso M, et al. Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors. Bioorg Med Chem Lett 2014;2:2617–20. (c) Temperini C, Innocenti A, Guerri A, et al. Phosph(on)ate as a zinc binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. Bioorg Med Chem Lett 2007;1:2210–15. (d) Luisi G, Angelini G, Gasbarri C, et al. Dual targeting of cancer-related human matrix metalloproteinases and carbonic anhydrases by chiral N-(biarylsulfonyl)-phosphonic acids. J Enzyme Inhib Med Chem 2017;32:1260–4.
   PubMed Web of Science ®Google Scholar
• (a) Alterio V, Cadoni R, Esposito D, et al. Benzoxaborole as a new chemotype for carbonic anhydrase inhibition. Chem Commun (Camb) 2016;5:11983–6. (b) Nocentini A, Cadoni R, Dumy P, et al. Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles. J Enzyme Inhib Med Chem 2018;33:286–9.
   Web of Science ®Google Scholar
• Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur J Med Chem 1996;31:1001–10.
   Web of Science ®Google Scholar
• Di Fiore A, Maresca A, Alterio V, et al. Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of N-substituted benzenesulfonamides to human isoform II. Chem Commun (Camb) 2011;47:11636–8.
   PubMed Web of Science ®Google Scholar
• Di Fiore A, Maresca A, Supuran CT, De Simone G. Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors. Chem Commun (Camb) 2012;48:8838–40.
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
   PubMed Web of Science ®Google Scholar
• Guthrie JP. Hydrolysis of esters of oxy acids: pKa values for strong acids. Can J Chem 1978;56:2342–54.
   Web of Science ®Google Scholar
• Remko M. Molecular structure, pKa, lipophilicity, solubility and absorption of biologically active aromatic and heterocyclic sulfonamides. J Mol Struct 2010;944:34–42.
   Web of Science ®Google Scholar
• Scott AD, Phillips C, Alex A, et al. Thermodynamic optimisation in drug discovery: a case study using carbonic anhydrase inhibitors. ChemMedChem 2009;4:1985–9.
   PubMed Web of Science ®Google Scholar
• (a) Winum JY, Vullo D, Casini A, et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 2003;4:2197–204. (b) Casini A, Winum JY, Montero JL, et al. Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives. Bioorg Med Chem Lett 2003;1:837–40. (c) Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;4:7024–31. (d) Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841–5.
   Web of Science ®Google Scholar
• (a) Tars K, Vullo D, Kazaks A, et al. Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. J Med Chem 2013;5:293–300. (b) Grandane A, Tanc M, Di Cesare Mannelli L, et al. 6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells. J Med Chem 2015;58:3975–83.
   Web of Science ®Google Scholar
• (a) Ferraroni M, Carta F, Scozzafava A, et al. Thioxocoumarins inhibit carbonic anhydrases through a different mechanism compared to coumarins. J Med Chem 2016;59:462–73. (b) Carta F, Temperini C, Innocenti A, et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem 2010;53:5511–22.
   PubMed Web of Science ®Google Scholar
• (a) Bayram E, Senturk M, Kufrevioglu OI, Supuran CT. In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem 2008;16:9101–5. (b) Supuran CT, Vullo D, Manole G, et al. Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2004;2:49–68. (c) Sentürk M, Gülçin I, Beydemir S, et al. In vitro inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds. Chem Biol Drug Des 2011;77:494–9. (d) Oztürk Sarikaya SB, Topal F, Sentürk M, et al. In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds. Bioorg Med Chem Lett 2011;21:4259–62. (e) Innocenti A, Gülçin I, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I–XV. Bioorg Med Chem Lett 2010;20:5050–3. (f) Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I–XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem 2008;16:7424–8.
   PubMed Web of Science ®Google Scholar
• (a) Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;1:3057–62. (b) Küçükbay FZ, Küçükbay H, Tanc M, et al. Synthesis and carbonic anhydrase inhibitory properties of amino acid - coumarin/quinolinone conjugates incorporating glycine, alanine and phenylalanine moieties. J Enzyme Inhib Med Chem 2016;31:1198–202. (c) Vullo D, Isik S, Bozdag M, et al. 7-Amino-3,4-dihydro-1H-quinolin-2-one, a compound similar to the substituted coumarins, inhibits α-carbonic anhydrases without hydrolysis of the lactam ring. J Enzyme Inhib Med Chem 2015;3:773–7. (d) Maresca A, Scozzafava A, Supuran CT. 7,8-Disubstituted – but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg Med Chem Lett 2010;20:7255–8.
   Web of Science ®Google Scholar
• (a) Scozzafava A, Carta F, Supuran CT. Secondary and tertiary sulfonamides: a patent review (2008–2012). Expert Opin Ther Pat 2013;2:203–13. (b) Alp C, Ozsoy S, Alp NA, et al. Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI. J Enzyme Inhib Med Chem 2012;2:818–24. (c) Le Darz A, Mingot A, Bouazza F, et al. Fluorinated pyrrolidines and piperidines containing tertiary benzenesulfonamides: selective carbonic anhydrase II inhibitors. J Enzyme Inhib Med Chem 2015;30:737–45.
   Web of Science ®Google Scholar
• (a) De Monte C, Carradori S, Secci D, et al. Cyclic tertiary sulfamates: selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N- and O-substituted acesulfame derivatives. Eur J Med Chem 2014;8:240–6. (b) D’Ascenzio M, Carradori S, Secci D, et al. Selective inhibition of human carbonic anhydrases by novel amide derivatives of probenecid: synthesis, biological evaluation and molecular modelling studies. Bioorg Med Chem 2014;22:3982–8. (c) Carradori S, Mollica A, Ceruso M, et al. New amide derivatives of probenecid as selective inhibitors of carbonic anhydrase IX and XII: biological evaluation and molecular modelling studies. Bioorg Med Chem 2015;23:2975–81.
   Web of Science ®Google Scholar
• Murray AB, Lomelino CL, Supuran CT, McKenna R. “Seriously Sweet”: acesulfame K exhibits selective inhibition using alternative binding modes in carbonic anhydrase isoforms. J Med Chem 2018; in press. doi: 10.1021/acs.jmedchem.7b01470.
   PubMed Web of Science ®Google Scholar